Proxy filing
Logotype for ResMed Inc

ResMed (RMD) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for ResMed Inc

Proxy filing summary

6 Nov, 2026

Executive summary

  • FY26 revenue rose 10% to $5.7B (8% in constant currency); non-GAAP diluted EPS grew 17%, free cash flow exceeded $1.6B, and capital returned exceeded $1B, up 72% YoY.

  • FY27 priorities: enhance and transform the core business and build for the future; expected share repurchases of ~$1.5B and total stockholder returns above $1.85B, including a 10% quarterly dividend increase to $0.66 per share.

  • Completed the $340M gross-price Noctrix Health acquisition, adding restless legs syndrome treatment; MatrixCare divestiture closed September 1, 2026, with proceeds primarily directed to an accelerated share repurchase.

Voting matters and shareholder proposals

  • Annual meeting scheduled virtually for November 18, 2026 (US) / November 19, 2026 (Australia); stockholders vote on 10 directors, PwC auditor ratification for FY27, and an advisory say-on-pay proposal; board recommends FOR all.

  • Each director nominee and Proposals 2 and 3 require a majority of votes cast; broker non-votes do not affect director or say-on-pay outcomes, while brokers may vote on auditor ratification.

  • 2025 say-on-pay received ~90% support, up from ~84% in 2024; the next annual advisory vote is scheduled for 2027.

Board of directors and corporate governance

  • Ten nominees stand for one-year terms; Ron Taylor retires after over 21 years, Carol Burt becomes lead director November 15, 2026, and board size decreases from 11 to 10 after the annual meeting.

  • Eight of 10 nominees are independent; independent directors meet in executive session at each board meeting, and all four standing committees have independent members and chairs.

  • FY26 board attendance was at least 75% for every director; the board conducts annual self-assessments, reviews strategy, and oversees CEO and executive succession planning, including an emergency plan.

  • CFO Brett Sandercock stepped down May 4, 2026; Aaron Bloomer succeeded him, with Sandercock serving as special advisor through December 2026 and as a consultant during 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ResMed